Loading...
•
Jun 30, 2021
Amicus Therapeutics Q2 2021 Earnings Report
Amicus Therapeutics reported financial results for Q2 2021, highlighting Galafold revenue growth and progress in regulatory submissions for AT-GAA.
Key Takeaways
Amicus Therapeutics announced its Q2 2021 financial results, featuring a 24% increase in Galafold revenue compared to Q2 2020. The company also completed the rolling BLA and NDA submissions to the U.S. FDA for AT-GAA in Pompe disease.
Total Galafold revenue reached $77.4 million, a 24% increase over Q2 2020.
The company is on track to achieve revenue guidance of $300 million to $315 million.
The rolling BLA and NDA submissions to the U.S. FDA for AT-GAA in Pompe disease were completed.
Positive EMA Rapporteur and Co-Rapporteur meeting supported the MAA submissions for AT-GAA, with global submissions on track in 2021.
Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics Revenue by Segment
Revenue by Segment
Galafold Revenue
CapyFin.com Forward Guidance
Amicus Therapeutics is on-track to achieve revenue guidance of $300M-$315M.